Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 350

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 350
---
 pharmaceutical industry, including global roles in business development, sales and marketing, medical as well as regulatory affairs, and general management. NLS complements its management team with a group of scientific and clinical advisors that includes internationally recognized North American and European experts in CNS disorders, including the areas of its current focus, rare hypersomnolence (specifically, narcolepsy) and complex neurodevelopmental disorders. NLS’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The SEC also maintains an internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. NLS’s filings with the SEC are available to the public through the SEC’s website at www.sec.gov. The information contained on, or that can be accessed through, NLS’s website or the SEC website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. NLS is an EGC. As such, NLS is eligible to, and intends to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes -OxleyAct. NLS could remain an EGC for up to five years, or until the earliest of (a) the last day of the first fiscal year in which NLS’s annual gross revenues exceeds $1.235billion, (b) the date that NLS becomes a “large accelerated filer” as defined in Rule 12b -2under the Exchange Act, which would occur if the market value of NLS Common Shares that is held by non -affiliatesexceeds $700million as of the last business day of its most recently completed second fiscal quarter, or (c) the date on which NLS issued more than $1billion in nonconvertible debt during the preceding three -yearperiod. NLS is a foreign private issuer as defined by the rules under the Securities Act and the Exchange Act. NLS’s status as a foreign private issuer also exempts it from compliance with certain laws and regulations of the SEC and certain regulations of Nasdaq, including the proxy rules, the